AGRANULOCYTOSIS FOLLOWING PHENYLBUTAZONE THERAPY

Publisher Website
Google Scholar
Abstract
We have recently observed a patient in whom agranulocytosis developed following treatment with the new antirheumatic drug phenylbutazone (butazolidin®). Because of the large number of patients who are potential users of phenylbutazone, it was thought advisable to report this severe toxic reaction as a warning against its indiscriminate use without constant and careful check on the status of the blood. REPORT OF A CASE Mrs. B. R., a 65-year-old white housewife, was admitted to Mt. Sinai Hospital on Sept. 24, 1952, complaining of fever, generalized aching pains, and a skin rash that had been present for four days. For the past 12 years she had had chronic rheumatoid arthritis, which had involved most of the joints of her extremities but which was worse in the knees and ankles. During acute exacerbations in the past, she had taken large doses of salicylates in various forms but no other medication. On Sept.

This publication has 0 references indexed in Scilit: